From conventional pathologic diagnosis to the molecular classification of breast carcinoma: Are we ready for the change?

Romanian Journal of Morphology and Embryology

Volumn 50, Issue 1, 2008, Pages 5-13

  Raica, M ^a   Jung, I ^b   Cîmpean, Anca Maria ^a   Suciu, C ^a   Mureşan, Anca Maria ^a  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Breast cancer; Immunohistochemistry; Molecular classification; Prognosis; Therapy

Indexed keywords

EID: 70249109724     PISSN: 12200522     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. MORRIS S. R., CAREY L. A., Molecular profiling in breast cancer, Rev Endocr Metab Disord, 2007, 8(3):185-198.
2. MOLL R., KREPLER R., FRANKE W. W., Complex cytokeratin polypeptide patterns observed in certain human carcinomas, Differentiation, 1983, 23(3):256-269.
3. GUSTERSON B. A., ROSS D. T., HEATH V. J., STEIN T., Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer, Breast Cancer Res, 2005, 7(4):143-148.
4. FOULKES W. D., BRCA1 functions as a breast stem cell regulator, J Med Genet, 2004, 41(1):1-5.
5. LAAKSO M., LOMAN N., BORG A., ISOLA J., Cytokeratin 5/14- positive breast cancer: true basal phenotype confined to BRCA1 tumors, Mod Pathol, 2005, 18(10):1321-1328.
6. DABBS D. J., CHIVUKULA M., CARTER G., BHARGAVA R., Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile, Mod Pathol, 2006, 19(11):1506-1511.
7. HUANG H. J., NEVEN P., DRIJKONINGEN M., PARIDAENS R., WILDIERS H., VAN LIMBERGEN E., BERTELOOT P., AMANT F., CHRISTIAENS M. R., VERGOTE I., Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related, Breast Cancer Res Treat, 2005, 91(1):81-87.
8. DAIDONE M. G., PARADISO A., GION M., HARBECK N., SWEEP F., SCHMITT M., Biomolecular features of clinical relevance in breast cancer, Eur J Nucl Med Mol Imaging, 2004, 31(Suppl 1):S3-14.
9. REIS-FILHO J. S., WESTBURY C., PIERGA J.-Y., The impact of expression profiling on prognostic and predictive testing in breast cancer, J Clin Pathol, 2006, 59(3):225-231.
10. MURAD T. M., SCHARPELLI D. G., The ultrastructure of medullary and scirrhous mammary duct carcinoma, Am J Pathol, 1967, 50(2):335-360.
11. POLYAK K., Breast cancer: origins and evolution, J Clin Invest, 2007, 117(11):3155-3163.
12. PEROU C. M., SØRLIE T., EISEN M. B., VAN DE RIJN M., JEFFREY S. S., REES C. A., POLLACK J. R., ROSS D. T., JOHNSEN H., AKSLEN L. A., FLUGE O., PERGAMENSCHIKOV A., WILLIAMS C., ZHU S. X., LØNNING P. E., BØRRESEN-DALE A. L., BROWN P. O., BOTSTEIN D., Molecular portraits of human breast tumours, Nature, 2000, 406(6797):747-752.
13. NIELSEN T. O., HSU F. D., JENSEN K., CHEANG M., KARACA G., HU Z., HERNANDEZ-BOUSSARD T., LIVASY C., COWAN D., DRESSLER L., AKSLEN L. A., RAGAZ J.,GOWN A. M., GILKS C. B., VAN DE RIJN M., PEROU C. M., Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma, Clin Cancer Res, 2004, 10(16):5367-5374.
14. CAREY L. A., PEROU C. M., LIVASY C. A., DRESSLER L. G., COWAN D., CONWAY K., KARACA G., TROESTER M. A., TSE C. K., EDMISTON S., DEMING S. L., GERADTS J., CHEANG M. C., NIELSEN T. O., MOORMAN P. G., EARP H. S., MILLIKAN R. C., Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study, JAMA, 2006, 295(21):2492-2502.
15. RAKHA E. A., EL-SAYED M. E., GREEN A. R., PAISH E. C., LEE A. H. S., ELLIS I. O., Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression, Histopathology, 2007, 50(4):434-438.
16. BIDARD F. C., CONFORTI R., BOULET T., MICHIELS S., DELALOGE S., ANDRÉ F., Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers, Ann Oncol, 2007, 18():1285-1286.
17. FARATIAN D., BARTLETT J., Predictive markers in breast cancer - the future, Histopathology, 2008, 52(1):91-98.
18. SHIN B. K., LEE Y., LEE J. B., KIM H. K., LEE J. B., CHO S. J., KIM A., Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status, Oncol Rep, 2008, 19(3):617-625.
19. LIVASY C. A., KARACA G., NANDA R., TRETIAKOVA M. S., OLOPADE O. I., MOORE D. T., PEROU C. M., Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma, Mod Pathol, 2006,19(2):264-271.
20. KORSCHING E., JEFFREY S. S., MEINERZ W., DECKER T., BOECKER W., BUERGER H., Basal carcinoma of the breast revisited: an old entity with new interpretations, J Clin Pathol, 2008, 61(5):553-560.
21. REIS-FILHO J. S., MILANEZI F., STEELE D., SAVAGE K., SIMPSON P. T., NESLAND J. M., PEREIRA E. M., LAKHANI S. R., SCHMITT F. C., Metaplastic breast carcinomas are basal-like tumours, Histopathology, 2006, 49(1):10-21.
22. REIS-FILHO J. S., TUTT A. N. J., Triple negative tumours: a critical review, Histopathology, 2008, 52(1):108-118.
23. JACQUEMIER J., PADOVANI L., RABAYROL I., LAKHANI S. R., PENAULT-LLORCA F., DENOUX Y., FICHE M., FIGUEIRO P., MAISONGROSSE V., LEDOUSSAL V., MARTINEZ PENUELA J., UDVARHELY N., EL MAKDISSI G., GINESTIER C., GENEIX J., CHARAFE-JAUFFRET E., XERRI L., EISINGER F., BIRNBAUM D., SOBOL H., EUROPEAN WORKING GROUP FOR BREAST SCREENING PATHOLOGY; BREAST CANCER LINKAGE CONSORTIUM, Typical medullary breast carcinomas have a basal/myoepithelial phenotype, J Pathol, 2005, 207(3):260-268.
24. HICKS D. G., SHORT S. M., PRESCOTT N. L., TARR S. M., COLEMAN K. A., YODER B. J., CROWE J. P., CHOUEIRI T. K., DAWSON A. E., BUDD G. T., TUBBS R. R., CASEY G., WEIL R. J., Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal CK5/6, and overexpress HER2 or EGFR, Am J Surg Pathol, 2006, 30(9):1097-1104.
25. VINCENT-SALOMON A., GRUEL N., LUCCHESI C., MACGROGAN G,. DENDALE R., SIGAL-ZAFRANI B., LONGY M., RAYNAL V., PIERRON G., DE MASCAREL I., TARIS C., STOPPA-LYONNET S., PIERGA J.-Y., SALMON R., SASTRE-GARAU X., FOURQUET A., DELATTRE O., DE CREMOUX P., AURIAS A., Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity, Breast Cancer Res, 2007, 9(2):R24.
26. CHEN M. H. S., YIP G. W. C., TSE G. M. K., MORIYA T., LUI P. C. W., ZIN M. L., BAY B. H., TAN P. H., Expression of basal keratins and vimentin in breast cancers of young women correlates with adverse pathologic parameters, Mod Pathol, 2008, 21(10):1183-1191.
27. BRYAN B. B., SCHNITT S. J., COLLINS L. C., Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer, Mod Pathol, 2006, 19(5):617-621.
28. PAREDES J., LOPES N., MILANEZI F., SCHMITT F. C., P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ, Virchows Arch, 2007, 450(1):73-80.
29. BERTUCCI F., FINETTI P., ROUGEMONT J., CHARAFE-JAUFFRET E., CERVERA N., TARPIN C., NGUYEN C., XERRI L., HOULGATTE R., JACQUEMIER J., VIENS P., BIRNBAUM D., Gene expression profiling identifies molecular subtypes of inflammatory breast cancer, Cancer Res, 2005, 65(6):2170-2178.
30. BANERJEE S., REIS-FILHO J. S., ASHLEY S., STEELE D., ASHWORTH A., LAKHANI S. R., SMITH I. E., Basal-like breast carcinomas: clinical outcome and response to chemotherapy, J Clin Pathol, 2006, 59(7):729-735.
31. VAN DE RIJN M., PEROU C. M., TIBSHIRANI R., HAAS P., KALLIONIEMI O., KONONEN J., TORHORST J., SAUTER G., ZUBER M., KÖCHLI O. R., MROSS F., DIETERICH H., SEITZ R., ROSS D., BOTSTEIN D., BROWN P., Expression of cytokeratin 17 and 5 identifies a group of breast carcinomas with poor clinical outcome, Am J Pathol, 2002, 161(6):1991-1996.
32. TISCHKOWITZ M., BRUNET J. S., BÉGIN L. R., HUNTSMAN D. G., CHEANG M. C. U., AKSLEN L. A., NIELSEN T. O., FOULKES W. D., Use of immunohistochemical markers can refine prognosis in triple negative breast cancer, BMC Cancer, 2007, 7:134.
33. FULFORD L. G., REIS-FILHO J. S., RYDER K., JONES C., GILLETT C. E., HANBY A., EASTON D., LAKHANI S. R., Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival, Breast Cancer Res, 2007, 9(1):R4.
34. rd Intercontinental Congress of Pathology, Barcelona, Spain, May 17-21, 2008, 22-25.
35. MCCARTHY A., SAVAGE K., GABRIEL A., NACEUR C., REIS-FILHO J. S., ASHWORTH A., A mouse model of basal-like breast carcinoma with metaplastic elements, J Pathol, 2007, 211(4):389-398.
36. SØRLIE T., WANG Y., XIAO C., JOHNSEN H., NAUME B., SAMAHA R. R., BØRRESEN-DALE A. L., Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analysis across three different platforms, BMC Genomics, 2006, 7:127.
37. MILLIKAN R. C., NEWMAN B., TSE C. K., MOORMAN P. G.,CONWAY K., DRESSLER L. G., SMITH L. V., LABBOK M. H., GERADTS J., BENSEN J. T., JACKSON S., NYANTE S., LIVASY C., CAREY L., EARP H. S., PEROU C. M., Epidemiology of basal-like breast cancer, Breast Cancer Res Treat, 2008, 109(1):123-139.
38. SØRLIE T., PEROU C. M., TIBSHIRANI R., AAS T., GEISLER S., JOHNSEN H., HASTIE T., EISEN M. B., VAN DE RIJN M., JEFFREY S. S., THORSEN T., QUIST H., MATESE J. C., BROWN P. O., BOTSTEIN D., EYSTEIN LØNNING P., BØRRESEN- DALE A. L., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci USA, 2001, 98(19):10869-10874.
39. LAAKSO M., TANNER M., NILSSON J., WIKLUND T., ERIKSTEIN B., KELLOKUMPU-LEHTINEN P., MALMSTRÖM P., WILKING N., BERGH J., ISOLA J., Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer, Clin Cancer Res, 2006, 12(14 Pt 1):4185-4191.
40. CHIVUKULA M., BHARGAVA R., BRUFSKY A., SURTI U., DABBS D. J., Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemicalscore 2+) cases, Mod Pathol, 2008, 21(4):363-368.
41. TAMIMI R. M., BAER H. J., MAROTTI J., GALAN M., GALABURDA L., FU Y., DEITZ A. C., CONNOLLY J. L., SCHNITT S. J., COLDITZ G. A., COLLINS L. C., Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer, Breast Cancer Res, 2008,10(4):R67.
42. TAN D. S. P., MARCHIÓ C., JONES R. L., SAVAGE K., SMITH I. E., DOWSETT M., REIS-FILHO J. S., Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients, Breast Cancer Res Treat, 2008, 111(1):27-44.
43. MULLAN P. B., MILLIKAN R. C., Molecular subtyping of breast cancer: opportunities for new therapeutic approaches, Cell Mol Life Sci, 2007, 64(24):3219-3232.
44. RAKHA E. A., EL-SAYED M. E., GREEN A. R., LEE A. H. S., ROBERTSON J. F., ELLIS I. O., Prognostic markers in triple-negative breast cancer, Cancer, 2007, 109(1):25-32.
45. FARMER P., BONNEFOI H., BECETTE V., TUBIANA-HULIN M., FUMOLEAU P., LARSIMONT D., MACGROGAN G., BERGH J., CAMERON D., GOLDSTEIN D., DUSS D., NICOULAZ A. L., BRISKEN C., FICHE M., DELORENZI M., IGGO R., Identification of molecular apocrine breast tumors by microarray analysis, Oncogene, 2005, 24(29):4660-4671.
46. DOANE A. S., DANSO M., LAL P., DONATON M., ZHANG L., HUDIS C., GERALD W. L., An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen, Oncogene, 2006, 25(28):3994-4008.
47. CONFORTI R., BOULET T., TOMASIC G., TARANCHON E.,ARRIAGADA R., SPIELMANN M., DUCOURTIEUX M., SORIA J. C., TURSZ T., DELALOGE S., MICHIELS S., ANDRE ́ F., Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials, Ann Oncol, 2007, 18(9):1477-1483.
48. SOTIRIOU C., NEO S. Y., MCSHANE L. M., KORN E. L., LONG P. M., JAZAERI A., MARTIAT P., FOX S. B., HARRIS A. L., LIU E. T., Breast cancer classification and prognosis based on gene expression profiles from a population-based study, Proc Natl Acad Sci USA, 2003, 100(18):10393-10398.
49. SØRLIE T., TIBSHIRANI R., PARKER J., HASTIE T., MARRON J. S., NOBEL A., DENG S., JOHNSEN H., PESICH R., GEISLER S., DEMETER J., PEROU C. M., LØNNING P. E., BROWN P. O., BØRRESEN-DALE A. L., BOTSTEIN D., Repeated observation of breast tumor subtypes in independent gene expression data sets, Proc Natl Acad Sci USA, 2003, 100(14):8418-8423.
50. ANDRÉ F., PUSZTAI L., Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy, Nat Clin Prot Oncol, 2006, 3(11):621-632.
51. BRENTON J. D., CAREY L. A., AHMED A. A., CALDAS C., Molecular classification and molecular forecasting of breast cancer: ready for clinical application?, J Clin Oncol, 2005, 23(29):7350-7360.
52. ROUZIER R., PEROU C. M., SYMMANS W. F., IBRAHIM N., CRISTOFANILLI M., ANDERSON K., HESS K. R., STEC J., AYERS M., WAGNER P., MORANDI P., FAN C., RABIUL I., ROSS J. S., HORTOBAGYI G. N., PUSZTAI L., Breast cancer molecular subtypes respond differently to preoperative chemotherapy, Clin Cancer Res, 2005, 11(16):5678-5685.
53. SOTIRIOU C., POWLES T. J., DOWSETT M., JAZAERI A. A., FELDMAN A. L., ASSERSOHN L., GADISETTI C., LIBUTTI S. K., LIU E. T., Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer, Breast Cancer Res, 2002, 4(3):R3.
54. HARRIS L. N., BROADWATER G., LIN N. U., MIRON A., SCHNITT S. J., COWAN D., LARA J., BLEIWEISS I., BERRY D., ELLIS M., HAYES D. F., WINER E. P., DRESSLER L., Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342, Breast Cancer Res, 2006, 8(6):R66.
55. PUSZTAI L., MAZOUNI C., ANDERSON K., WU Y., SYMMANS W. F., Molecular classification of breast cancer: limitations and potential, Oncologist, 2006, 11(8):868-877.
56. AZOULAY S., LAÉ M., FRÉNEAUX P., MERLE S., AL GHUZLAN A., CHNECKER C., ROSTY C., KLIJANIENKO J, SIGAL-ZAFRANI B., SALMON R., FOURQUET A., SASTRE- GARAU X., VINCENT-SALOMON A., KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome, Mod Pathol, 2005, 18(12):1623-1631.
57. BURSTEIN H. J., ELIAS A. D., RUGO H. S., COBLEIGH M. A., WOLFF A. C., EISENBERG P. D., LEHMAN M., ADAMS B. J., BELLO C. L., DEPRIMO S. E., BAUM C. M., MILLER K. D., Phase II study of sunitinib, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxanes, J Clin Oncol, 2008, 26(11):1810-1816.
58. RAKHA E. A., EL-SAYED M. E., REIS-FILHO J. S., ELLIS I. O., Expression profiling technology: its contribution to our understanding of breast cancer, Histopathology, 2008, 52(1):67-81.